PURPOSE: The expression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) is associated with poor prognosis in sporadic colorectal carcinoma (CRC). EGFR inhibitors are approved for the treatment of refractory CRC. The aim of this study was to investigate the expression of EGFR and HER2 and downstream extracellular signal regulated kinase (ERK) and mitogen activated protein kinase (MAPK) in non-neoplastic colonic mucosa, adenomas and carcinomas from familial adenomatous polyposis coli (FAP) patients, exploring the expression along the adenoma-carcinoma sequence. METHODS: The expression of EGFR, HER2, phosphorylated MAPK/ERK kinase (pMEK) and phosphorylated ERK (pERK) proteins was studied by immunohistochemistry in samples of colonic non-neoplastic mucosa (n = 65), adenomas (n = 149) and adenocarcinomas (n = 16) from each of the 16 FAP patients. RESULTS: For HER2, only weak cytoplasmic expression was seen in 8% of adenomas, 6% of carcinomas and 3% of the non-neoplastic mucosa. EGFR was expressed in non-neoplastic mucosa, adenomas and carcinomas with a statistically significant increase in expression in adenomas compared with non-neoplastic mucosa (p < 0.001). There was also a statistically significant increase in nuclear staining intensity for pERK (p < 0.001) and pMEK (p < 0.001) in adenomas compared to non-neoplastic mucosa. CONCLUSIONS: This is the first study investigating the expression of these receptors in non-neoplastic mucosa, adenomas and carcinomas from FAP patients. HER2 is not upregulated in the tumours of FAP patients, while EGFR appears to be upregulated in most adenomas and carcinomas, with associated upregulation of pERK and pMEK. We conclude that EGFR and downstream members of its signalling pathway, but not HER2, may be potential therapeutic targets in FAP patients.
PURPOSE: The expression of epidermal growth factor receptor (EGFR) and humanepidermal growth factor receptor 2 (HER2) is associated with poor prognosis in sporadic colorectal carcinoma (CRC). EGFR inhibitors are approved for the treatment of refractory CRC. The aim of this study was to investigate the expression of EGFR and HER2 and downstream extracellular signal regulated kinase (ERK) and mitogen activated protein kinase (MAPK) in non-neoplastic colonic mucosa, adenomas and carcinomas from familial adenomatous polyposis coli (FAP) patients, exploring the expression along the adenoma-carcinoma sequence. METHODS: The expression of EGFR, HER2, phosphorylated MAPK/ERK kinase (pMEK) and phosphorylated ERK (pERK) proteins was studied by immunohistochemistry in samples of colonic non-neoplastic mucosa (n = 65), adenomas (n = 149) and adenocarcinomas (n = 16) from each of the 16 FAPpatients. RESULTS: For HER2, only weak cytoplasmic expression was seen in 8% of adenomas, 6% of carcinomas and 3% of the non-neoplastic mucosa. EGFR was expressed in non-neoplastic mucosa, adenomas and carcinomas with a statistically significant increase in expression in adenomas compared with non-neoplastic mucosa (p < 0.001). There was also a statistically significant increase in nuclear staining intensity for pERK (p < 0.001) and pMEK (p < 0.001) in adenomas compared to non-neoplastic mucosa. CONCLUSIONS: This is the first study investigating the expression of these receptors in non-neoplastic mucosa, adenomas and carcinomas from FAPpatients. HER2 is not upregulated in the tumours of FAPpatients, while EGFR appears to be upregulated in most adenomas and carcinomas, with associated upregulation of pERK and pMEK. We conclude that EGFR and downstream members of its signalling pathway, but not HER2, may be potential therapeutic targets in FAPpatients.
Authors: J Randolph Hecht; Edith Mitchell; Marcus A Neubauer; Howard A Burris; Paul Swanson; Timothy Lopez; Glenn Buchanan; Maureen Reiner; Jennifer Gansert; Jordan Berlin Journal: Clin Cancer Res Date: 2010-03-23 Impact factor: 12.531
Authors: W F Bodmer; C J Bailey; J Bodmer; H J Bussey; A Ellis; P Gorman; F C Lucibello; V A Murday; S H Rider; P Scambler Journal: Nature Date: 1987 Aug 13-19 Impact factor: 49.962
Authors: Reinhard Kopp; Elisabeth Rothbauer; Elisabeth Mueller; Friedrich Wilhelm Schildberg; Karl-Walter Jauch; Andreas Pfeiffer Journal: Dis Colon Rectum Date: 2003-10 Impact factor: 4.585
Authors: Y Baba; K Nosho; K Shima; J A Meyerhardt; A T Chan; J A Engelman; L C Cantley; M Loda; E Giovannucci; C S Fuchs; S Ogino Journal: Br J Cancer Date: 2010-08-31 Impact factor: 7.640
Authors: Wiesław Janusz Kruszewski; Robert Rzepko; Maciej Ciesielski; Jarosław Szefel; Jacek Zieliński; Mariusz Szajewski; Wojciech Jasiński; Krzysztof Kawecki; Janusz Wojtacki Journal: Dis Markers Date: 2010 Impact factor: 3.434
Authors: S Vicent; J M López-Picazo; G Toledo; M D Lozano; W Torre; C Garcia-Corchón; C Quero; J-C Soria; S Martín-Algarra; R G Manzano; L M Montuenga Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640
Authors: Naveen K Neradugomma; Dharmalingam Subramaniam; Ossama W Tawfik; Vincent Goffin; T Rajendra Kumar; Roy A Jensen; Shrikant Anant Journal: Carcinogenesis Date: 2013-11-21 Impact factor: 4.944
Authors: Marine Fidelle; Satoru Yonekura; Marion Picard; Alexandria Cogdill; Antoine Hollebecque; Maria Paula Roberti; Laurence Zitvogel Journal: Front Immunol Date: 2020-12-14 Impact factor: 7.561